Using microbes to improve treatment for pancreatic cancer
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10914782
This study is exploring a new way to help people with pancreatic cancer by using specially designed microbes that can break down tough tissue around tumors, making it easier for treatments to work better and with fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10914782 on ClinicalTrials.gov |
What this research studies
This research focuses on addressing the challenges of pancreatic ductal adenocarcinoma (PDAC), particularly the dense fibrous tissue that hampers effective treatment. The approach involves using engineered microbes that can produce enzymes to break down the extracellular matrix components, specifically hyaluronan and collagen, which contribute to the tumor's protective environment. By targeting these components, the goal is to enhance drug delivery and improve the effectiveness of cancer therapies while minimizing side effects. Patients may benefit from a more effective treatment option that directly addresses the barriers to drug penetration in tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While targeting the extracellular matrix in cancer treatment is a novel approach, similar strategies have shown promise in other cancer types, indicating potential for success in this area.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MANUEL, EDWIN — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: MANUEL, EDWIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Cause, Cancer Drug, Cancer Etiology, Cancer Patient